Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II/III Double-blind Randomized Placebo-controlled Trial Assessing the Preventive Effect of Clopidogrel on the Systemic Sclerosis Development Risk in Subjects With Specific Dysimmunity and Raynaud Phenomenon

NCT05098704 is registered in ClinicalTrials.gov with University Hospital, Bordeaux as lead sponsor.

NCT NCT05098704
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05098704 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II/III Double-blind Randomized Placebo-controlled Trial Assessing the Preventive Effect of Clopidogrel on the Systemic Sclerosis Development Risk in Subjects With Specific Dysimmunity and Raynaud Phenomenon
Lead sponsor
University Hospital, Bordeaux
Phase
Phase 2/3
Overall status
Recruiting
Start date
June 22, 2022
Completion date
June 30, 2032
Enrollment
90 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

scleroderma, systemic sclerosis